Improving the "real life" management of schizophrenia spectrum disorders by LAI antipsychotics: A one-year mirror-image retrospective study in community mental health services.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
08
08
2019
accepted:
20
02
2020
entrez:
11
3
2020
pubmed:
11
3
2020
medline:
20
6
2020
Statut:
epublish
Résumé
Schizophrenia poses a significant economic burden on the healthcare system as well as it has a significant impact on society at large. Reasons for such a high economic burden of schizophrenia include the frequent relapses and hospitalizations occurring in this disorder. We analyze the effectiveness of long-acting injectable antipsychotics (LAIs) compared to oral medications, in terms of "clinical process management" in a sample of patients with a diagnosis of schizophrenia spectrum disorder treated in community mental health centers. An observational, retrospective, mirror-image study was carried out to evaluate the effectiveness of LAIs compared to oral medications in terms of number of hospitalizations, emergency visits and planned visits on a 10-year period (from July 2007 to June 2017). Differences between first and second generation LAIs were also explored. Our findings show that hospitalization and emergency visits are significantly decreased with the use of LAIs, while planned visits are increased in patients treated with LAIs. Our results suggest that LAIs, in particular, second generation ones, reduce hospitalization rates and emergency visits, improving the economic burden of schizophrenia. Therefore, LAIs should be considered a cost-effective treatment in the management of schizophrenia under routine conditions.
Identifiants
pubmed: 32155207
doi: 10.1371/journal.pone.0230051
pii: PONE-D-19-20664
pmc: PMC7064243
doi:
Substances chimiques
Antipsychotic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0230051Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Patient Educ Couns. 2013 Oct;93(1):73-9
pubmed: 23856552
J Clin Psychiatry. 2013 Oct;74(10):957-65
pubmed: 24229745
Psychiatry Res. 2010 Apr 30;176(2-3):109-13
pubmed: 20185182
Patient Prefer Adherence. 2017 Mar 23;11:619-629
pubmed: 28356723
Clin Drug Investig. 2017 Jun;37(6):559-569
pubmed: 28361438
J Med Econ. 2013 Jul;16(7):917-25
pubmed: 23663091
Schizophr Bull. 2014 Jan;40(1):192-213
pubmed: 23256986
JAMA Psychiatry. 2017 Jul 1;74(7):686-693
pubmed: 28593216
World Psychiatry. 2014 Feb;13(1):98-9
pubmed: 24497262
J Manag Care Spec Pharm. 2015 Sep;21(9):754-68
pubmed: 26308223
Cochrane Database Syst Rev. 2012 May 16;(5):CD008016
pubmed: 22592725
Adv Ther. 2013 Mar;30(3):286-97
pubmed: 23483449
Schizophr Res. 2014 Jul;156(2-3):228-32
pubmed: 24842538
Psychiatry Investig. 2015 Oct;12(4):425-33
pubmed: 26508952
J Clin Psychiatry. 2006 Mar;67(3):453-60
pubmed: 16649833
CNS Neurol Disord Drug Targets. 2017;16(8):857
pubmed: 29474168
Arch Gen Psychiatry. 2005 Jul;62(7):717-24
pubmed: 15997012
Neuropsychiatr Dis Treat. 2019 Jan 07;15:183-198
pubmed: 30662264
Schizophr Res. 2017 Jul;185:96-100
pubmed: 28119036